Voyager Therapeutics, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also reports unaudited fourth-quarter results. Voyager is a clinical-stage CNS gene-therapy company with no product sales; its reported revenue came from its Sanofi-Genzyme collaboration.
Financial and operating results
| Metric | FY2016 | FY2015 |
|---|---|---|
| Collaboration revenue | $14.2 million | $17.3 million |
| Research and development expense | $42.2 million | $27.7 million |
| General and administrative expense | $13.3 million | $9.9 million |
| Total operating expenses | $55.5 million | $37.6 million |
| Operating loss | $41.3 million | $20.3 million |
| Net loss | $40.2 million | $29.7 million |
| Net loss per share, basic and diluted | $1.59 | $9.14 |
| Net cash used in operating activities | $42.5 million | Cash provided: $41.3 million |
| Cash, cash equivalents and marketable debt securities at year-end | $174.4 million | $224.3 million |
| Working capital at year-end | $165.0 million | $172.0 million |
Fourth-quarter 2016 collaboration revenue was $2.4 million, operating expenses were $16.2 million, and net loss was $14.7 million, or $0.57 per share. No product gross margin was reported because the company had no product sales. The filing reports no conventional debt balance; total liabilities were $53.6 million, including $41.6 million of deferred collaboration revenue and lease-related liabilities. Operating lease commitments totaled $29.8 million.
Cash and investment resources fell by approximately $49.9 million year over year. Management said existing cash, cash equivalents and marketable debt securities were expected to fund operating expenses and capital expenditure requirements into 2019, based on its then-current operating plan. The company reported no off-balance-sheet arrangements.
Changes versus the prior year
- Revenue declined $3.1 million, while operating expenses increased $17.9 million and net loss widened $10.5 million.
- R&D expense rose $14.6 million, primarily from greater platform and process development, external research and manufacturing work, increased staffing, facility costs and licensing.
- FY2015 operating cash flow included the $65 million Sanofi-Genzyme upfront cash payment; FY2016 operating cash use was $42.5 million.
- During 2016, Voyager revised collaboration performance-period estimates, reduced expected in-kind services and paused/deprioritized VY-SMN101. The changes reduced recognized collaboration revenue by about $2.4 million per quarter prospectively; the filing says no further VY-SMN101 revenue was being recognized.
- Loss per share is not directly comparable year over year: the IPO and preferred-stock conversion substantially increased shares outstanding in late 2015.
Business, outlook and material developments
- Voyager’s six CNS programs were VY-AADC01/02 for advanced Parkinson’s disease; VY-SOD101 for SOD1-related ALS; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; VY-TAU01 for FTD/Alzheimer’s disease; and VY-NAV01 for severe chronic pain. VY-AADC01 was the only clinical-stage candidate described; other programs were preclinical or research-stage.
- Interim Phase 1b data for VY-AADC01 Cohorts 1 and 2 showed increased putamen coverage and AADC activity, reduced medication use, and improvements in several motor-function and patient-diary measures. The trial was open-label and small; the filing cautions that earlier uncontrolled results may not establish efficacy. Cohort 3 data were planned for mid-2017, and a larger double-blind, placebo-controlled trial was planned for Q4 2017.
- Voyager selected VY-SOD101 as a clinical candidate in early 2017, with an IND filing targeted for late 2017. The company planned two additional IND filings over the following 24 months, for Huntington’s and Friedreich’s ataxia programs.
- VY-AADC02 was planned for trials using Voyager’s baculovirus/Sf9 manufacturing process, replacing the HEK 293 production platform used for VY-AADC01. Comparability testing and preclinical evaluation were required; success was not assured.
- The Sanofi-Genzyme collaboration provided $65 million upfront cash, a $30 million equity investment and an in-kind commitment. Voyager may receive option and milestone payments, including up to $645 million in specified milestones, plus royalties; these amounts are contingent and are not guaranteed revenue. Voyager retains U.S. rights to most partnered programs and worldwide rights to VY-SOD101, VY-TAU01 and VY-NAV01.
- Management expected continued significant R&D spending and operating losses. The company may need additional financing; equity financing could dilute shareholders, and acceptable financing may not be available.
Risks, contingencies and unusual items
- Clinical and regulatory risk is high: gene therapy is relatively novel, the lead program was early-stage, and positive early findings may not be replicated in controlled or later-stage trials. Brain surgery and delivery introduce procedural risks; prior studies included hemorrhages, and the ongoing trial included a pulmonary embolism and related arrhythmia attributed by investigators to the procedure and immobility.
- Manufacturing scale-up, cGMP compliance and the switch to a new production platform could delay trials or require additional work. Voyager relied on third-party manufacturers and suppliers.
- Reliance on the ClearPoint delivery system is a concentration risk. The filing noted the supplier’s disclosed going-concern concerns and Voyager’s efforts to secure manufacturing know-how and an alternative supply path.
- Sanofi-Genzyme options, future milestone and royalty receipts, and continued collaboration support depend on development progress and partner decisions. Sanofi-Genzyme could terminate for convenience.
- Additional risks include competition, intellectual-property disputes and license dependence, uncertain reimbursement and market acceptance, and the need for future capital. The company had no material legal proceedings at year-end.
- The 2015 net loss included a $9.8 million noncash expense from remeasurement of preferred-stock tranche rights; that liability was settled in 2015. FY2016 included a $52,000 income-tax provision. Management reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor issued an unqualified opinion on the financial statements.
Most important facts for investors to verify
- Whether later controlled VY-AADC01 trials confirm clinically meaningful benefit and acceptable safety, beyond the small open-label interim data.
- Whether Cohort 3, posterior-trajectory studies and VY-AADC02 comparability work meet the disclosed timelines and technical objectives.
- Actual cash consumption and runway relative to management’s estimate through 2019, including future trial, manufacturing and facility spending.
- How collaboration revenue recognition changes, Sanofi-Genzyme option decisions and any resulting payments affect reported revenue and funding.
- Progress toward the targeted VY-SOD101 IND and the planned Huntington’s and Friedreich’s ataxia INDs, and whether manufacturing capacity can support them.